参芪抑瘤方联合化疗对骨肉瘤患者免疫功能、免疫球蛋白和生活质量的影响

Effect of shenqi yiliu recipe combined with chemotherapy on immune function,immunoglobulin and quality of life in patients with osteosarcoma

目的 探讨参芪抑瘤方联合化疗对骨肉瘤患者免疫功能、免疫球蛋白和生活质量的影响。方法 依据治疗方法的不同将120例骨肉瘤患者分为观察组和对照组,每组60例,对照组患者给予阿奇霉素;顺铂化疗,观察组患者在此基础上给予参芪抑瘤方辅助治疗。比较两组患者免疫功能指标[CD3^(+)、CD4^(+)、CD8^(+)、自然杀伤(NK)细胞,计算CD4^(+)/CD8^(+)]、免疫球蛋白(IgM、IgA、IgG)水平、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]和不良反应发生情况。结果 治疗后,两组患者CD3^(+)、CD4^(+)、NK细胞水平和CD4^(+)/CD8^(+)均低于本组治疗前(P﹤0.05),CD8^(+)水平均高于本组治疗前(P﹤0.05),观察组患者CD3^(+)、CD4^(+)、NK细胞水平和CD4^(+)/CD8^(+)均高于对照组(P﹤0.05),CD8^(+)水平低于对照组(P﹤0.05)。治疗后,两组患者IgM、IgA、IgG水平均低于本组治疗前(P﹤0.05),但观察组IgM、IgA、IgG水平均高于对照组(P﹤0.05)。治疗后,两组患者EORTC QLQ-C30量表各维度评分均高于本组治疗前(P﹤0.05),且观察组患者EORTC QLQ-C30量表各维度评分均高于对照组(P﹤0.05)。两组患者白细胞减少、血小板减少、恶心呕吐、转氨酶升高、周围神经毒性发生率均无明显差异(P﹥0.05)。结论 骨肉瘤患者在化疗基础上予以参芪抑瘤方辅助治疗,可进一步稳定免疫球蛋白水平及免疫功能,改善生活质量,且安全性较高。

Objective To investigate the effect of shenqi yiliu recipe combined with chemotherapy on immune function, immunoglobulin and quality of life in patients with osteosarcoma. Method A total of 120 patients with osteosarcoma were divided into observation group and control group according to the treatment method, with 60 cases in each group. The patients in the control group were given azithromycin;cisplatin chemotherapy, while the patients in the observation group were given adjuvant therapy with shenqi yiliu recipe based on the control group. Immune function indicators [CD3^(+), CD4^(+), CD8^(+), natural killer(NK) cell, calculation CD4^(+)/CD8^(+)], immunoglobulin [immunoglobulin(Ig) M,IgA, IgG] levels, quality of life [European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)], and occurrence of adverse events were compared between the two groups of patients.Result After the treatment, the levels of CD3^(+), CD4^(+), NK cell, and CD4^(+)/CD8^(+)in the two groups were lower than those in the same group before the treatment(P<0.05), and the levels of CD8^(+)were higher than themselves before the treatment(P<0.05). However, the levels of CD3^(+), CD4^(+), NK cell, and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group(P<0.05), and the level of CD8^(+)was lower than that in the control group(P<0.05). After the treatment, the levels of IgM, IgA, and IgG in the two groups were lower than those in the same group before the treatment(P<0.05), and the levels of IgM, IgA, and IgG in the observation group were higher than those in the control group(P<0.05).After the treatment, the scores of each dimension of the EORTC QLQ-C30 scale in the two groups were higher than those in the same group before the treatment(P<0.05), and the scores of each dimension of the scale in the observation group were higher than those in the control group(P<0.05). There were no significant differences in the incidence of adverse events including leukopenia, thrombocytopenia, nausea and vomiting, elevated transaminase, and peripheral neurotoxicity between the two groups(P>0.05). Conclusion Adjuvant therapy with shenqi yiliu recipe for osteosarcoma patients based on the chemotherapy regimen can further stabilize the level of immunoglobulin and immune function, improve patients’ quality of life with reliable safety.